BOSTON and LONDON, Aug. 21, 2024 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY. A fireside chat is scheduled for Wednesday, September 4th at 1:05 PM ET.
The live audio webcast of this event, as well as an archived recording, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/events-presentations.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients. Our most advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders and an immuno-oncology program focused on our LockBody technology platform. We operate with the conviction that each one of our programs has the potential to change the current treatment paradigm and establish a new standard of care. For more information, visit www.centessa.com, which does not form part of this release.
Contact:
Kristen K. Sheppard, Esq.
SVP of Investor Relations
investors@centessa.com


Đề xuất
Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach
Weihai Global Partner Business Center Undertakes Investment Promotion Activities in Xi’an
Feldspar unveils world’s first surface-based force measurement platform, announces engineering partnership and opens capital raise
A Paradise Acquisition Corp. Announces Intention to Voluntarily Delist from The Nasdaq Stock Market LLC, Conditional Upon Consummation of its Pending Business Combination with Enhanced Ltd
Sondo AI Marks One-Year Milestone as One of the Hottest AI Music Video Generators Transforming Music Video Creation
Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026